My name is Maureen , and I was diagnosed with Myeloma in 2017 at the age of 55 and was fortunate to have been invited to join a clinical trial. This was successful and my myeloma is currently in remission and being monitored. My diagnosis was life-changing, but I refuse to let myeloma define me. The…
My name is Ritva, and I live in Finland. I got my myeloma diagnosis four and a half years ago, when I was 63 years old. The first days after the diagnosis, I thought this is only a bad dream, but I had to accept the fact that myeloma was now part of my life.…
My name is Ariunsanaa and last year my mother was diagnosed with myeloma. At that time, both my sibling and I were living abroad. We soon realised there was no available treatment in our hometown, so we made the difficult decision to move her to an overseas location where she could receive proper care. Hearing…
My name is Wouter, I am living in The Netherlands, and I am 55 years old. In March 2024, I was diagnosed with myeloma, which turned my world upside down. One of the biggest challenges I faced was the physical pain caused by my broken vertebrae. Learning to manage that pain while also coming to…
Among the biggest policy initiatives targeting cancer at the European Union (EU) level, Europe’s Beating Cancer Plan is one of the most important and ambitious. Launched in 2021, it set to “tackle the entire disease pathway, from prevention to quality of life of cancer patients and survivors”. On 4 February 2025 the European Commission published…
We are proud to highlight the work of one of our Polish members, Fundacja Carita, which recently organised the European Forum of Hemato-Oncological Patients. This forum brought together experts and stakeholders to discuss crucial topics in haematology and patient advocacy. The event featured 12 discussion panels and lectures, delivered by 28 distinguished speakers from fields…
The European Young Myeloma Patients Group, created by Myeloma Patients Europe (MPE), invites you to a webinar focused on myeloma and physical fitness on Wednesday, 26 February 2025, from 16:00 – 17:00 CET. This session will be led by Ana Bernardino, PhD scholar in Human Motricity at the Faculty of Human Kinetics (FMH) at the…
On 22 January 2025, the European Commission approved an isatuximab combination for the treatment of newly diagnosed myeloma patients who are not eligible for a stem cell transplant in the EU. This follows a positive recommendation from the Committee for Medicinal Product for Human Use (CHMP) in November 2024. The CHMP is the European Medicines Agency’s…
